Ritmole Tablet 150mg (Propafenone Hydrochloride)

Adult dose

The individual maintenance dose should be determined under cardiac monitoring, including ECG monitoring and repeated blood pressure measurements. Adults: Administer 450-600㎎ of propafenone hydrochloride orally per day (one 150mg tablet 3 times daily or one 300mg tablet 2 times daily). In some cases, the dose may be increased to 900㎎ per day (one 300mg tablet or two 150mg tablets 3 times daily). This dosage regimen applies to patients weighing approximately 70㎏. For patients weighing less, the daily dose should be reduced according to body weight. The daily dose may be exceeded only in exceptional circumstances under the strict supervision of a cardiologist. In particular, in elderly patients, patients with a history of myocardial injury, and patients with hepatic or renal impairment, begin treatment at a low dose and increase cautiously while monitoring whether the blood concentration is appropriate. The first dose increase should be made after at least 3-4 days. Patients with ventricular arrhythmias require careful cardiac examination at the start of treatment. In these patients, treatment should be initiated only when emergency cardiac equipment is available and monitoring can be ensured; regular examinations are required during treatment (for example, standard ECG at one-month intervals, Holter monitoring at 3-month intervals, and exercise ECG if possible). If ECG changes occur, such as a QRS widening or QT prolongation greater than 25%, PR prolongation greater than 50%, QT prolongation greater than 500ms, or an increase in the frequency or severity of arrhythmias, a decision must be made as to whether to continue treatment. This medicine has a bitter taste and surface anesthetic effect, so swallow it with a small amount of liquid after meals. When prescribing this medicine, consider that there is no evidence that treatment with ClassⅠ antiarrhythmic agents helps prolong life.

This drug is specifically used for the treatment of cardiac arrhythmias and can affect cardiac function, so patients with heart disease should be particularly cautious. Caution should be exercised when used in patients with ventricular arrhythmias within 2 years after a myocardial infarction, as it may increase the risk of death. It should not be used in patients with severe heart failure with significantly reduced left ventricular function, cardiogenic shock, or certain cardiac conduction disorders. Patients with Brugada syndrome, severe bradycardia, those within 3 months post-myocardial infarction, severe obstructive pulmonary disease, or myasthenia gravis should also refrain from taking this medication. Patients with impaired liver or kidney function may have increased drug concentrations, so dose adjustments and monitoring of their condition are necessary. Various side effects can occur, including decreased heart rate, ECG abnormalities, lowered blood pressure, dizziness, nausea, liver function abnormalities, etc. If any abnormal symptoms appear, immediate consultation with healthcare providers is advised. Particularly, cardiac-related adverse reactions can be serious, so regular ECG tests and monitoring of the patient's condition are important. Caution is needed when driving or operating machinery while taking this medication, and alcohol consumption can exacerbate these side effects. There is a high possibility of drug interactions, so co-administration should be discussed with a doctor or pharmacist, and some drugs are prohibited from being taken together. During pregnancy, fetal and neonatal signs of arrhythmia should be carefully monitored, and during breastfeeding, administration should be avoided or breastfeeding should be discontinued if possible. Safety in children has not been established, so pediatric use must be decided with caution. The elderly are at greater risk of side effects due to decreased liver and kidney function, so start with a lower dose and frequently monitor the patient's condition. In case of overdose, symptoms like cardiac dysfunction, seizures, and hypotension may occur, necessitating immediate emergency treatment. This drug should only be administered when other antiarrhythmic medications are ineffective or not available, and the patient's condition must be closely monitored during treatment.

Significant decrease in heart rate (bradycardia), conduction disorders (atrioventricular block or ventricular block), increase in heart rate (palpitations), ventricular fibrillation, total arrhythmia, ventricular tachycardia (including torsades de pointes), ventricular flutter, worsening heart failure, orthostatic hypotension, postural hypotension, nausea, decreased appetite, abdominal bloating, vomiting, constipation, thirst, abdominal pain, bitter taste, numbness of the mouth, diarrhea, gastric pain, liver cell damage, cholestasis, jaundice, hepatitis, dizziness, headache, syncope, extrapyramidal symptoms, fatigue, ataxia, sensory disturbances, anxiety, nightmares, sleep disorders, seizures, restlessness, confusion, unsteady symptoms, leukopenia, neutropenia, thrombocytopenia, agranulocytosis, skin erythema, itching, urticaria, erythema, rash, hepatitis, allergic reactions, hypersensitivity reactions, anorexia nervosa, blurred vision, lupus syndrome, erectile dysfunction, fatigue, chest pain, elevated liver enzymes, warm sensation, flushing, lethargy, myalgia, edema, increased triglycerides, convulsions, bronchospasm, decreased libido, decreased sperm count, symptoms of Brugada syndrome or changes in electrocardiogram

This medication should be stored in a tightly closed container to prevent air or moisture ingress. The recommended storage temperature is room temperature between 1 degree and 30 degrees Celsius.

Appearance

White, round, film-coated tablets

Package unit

30 tablets/bottle, 60 tablets/bottle